Published in Ann Neurol on November 01, 2000
Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol (2004) 5.29
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest (2003) 2.60
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res (2005) 1.85
Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int (2008) 1.76
12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol (2004) 1.71
Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry (2007) 1.68
Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci (2008) 1.64
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61
Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest Ophthalmol Vis Sci (2008) 1.47
Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol (2007) 1.41
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia. Alzheimers Dement (2006) 1.34
The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci (2011) 1.31
Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta (2013) 1.29
Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med (2010) 1.27
Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis (2009) 1.26
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med (2010) 1.24
Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol (2005) 1.19
Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest (2003) 1.19
Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med (2008) 1.19
Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. Alzheimers Dement (2014) 1.15
Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol (2010) 1.14
Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med (2010) 1.12
The isoprostanes--25 years later. Biochim Biophys Acta (2014) 1.11
The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging (2007) 1.07
Heat shock proteins as biomarkers for the rapid detection of brain and spinal cord ischemia: a review and comparison to other methods of detection in thoracic aneurysm repair. Cell Stress Chaperones (2010) 1.07
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol (2009) 1.06
Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol (2005) 1.04
Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest (2005) 1.04
Antioxidant therapies for Alzheimer's disease. Oxid Med Cell Longev (2012) 1.03
Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease. Neurobiol Aging (2008) 1.02
Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J Biol Chem (2007) 1.01
Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry (2010) 0.98
Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. Int J Cell Biol (2012) 0.96
Oxidative balance score, colorectal adenoma, and markers of oxidative stress and inflammation. Cancer Epidemiol Biomarkers Prev (2014) 0.95
Oxidative damage and cognitive dysfunction: antioxidant treatments to promote healthy brain aging. Neurochem Res (2008) 0.95
CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis (2010) 0.94
Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J Alzheimers Dis (2010) 0.93
Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity. Brain Pathol (2005) 0.92
Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity. PLoS One (2012) 0.90
The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol Dis (2013) 0.88
Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis (2011) 0.88
Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegener (2007) 0.88
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy. Acta Neuropathol (2010) 0.86
Isoprostane F2alpha-VI, a new marker of oxidative stress, increases following light damage to the mouse retina. Mol Vis (2007) 0.85
Electrophilic cyclopentenone isoprostanes in neurodegeneration. J Mol Neurosci (2007) 0.85
Blood markers of oxidative stress in Alzheimer's disease. J Cell Mol Med (2012) 0.83
Evidence from clinical trials: can we do better? NeuroRx (2004) 0.83
Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease. ACS Chem Neurosci (2012) 0.83
Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis (2010) 0.82
Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations. Dement Geriatr Cogn Disord (2012) 0.82
Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro. Transfusion (2013) 0.81
Simulating obstructive sleep apnea patients' oxygenation characteristics into a mouse model of cyclical intermittent hypoxia. J Appl Physiol (1985) (2014) 0.81
Alzheimer's Disease, Diagnosis and the Need for Biomarkers. Biomark Insights (2008) 0.81
Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. Arch Toxicol (2015) 0.79
Antioxidants in the canine model of human aging. Biochim Biophys Acta (2011) 0.79
Upregulation of glycolytic enzymes, mitochondrial dysfunction and increased cytotoxicity in glial cells treated with Alzheimer's disease plasma. PLoS One (2015) 0.78
Biomarkers of Alzheimer's disease: from central nervous system to periphery? Int J Alzheimers Dis (2010) 0.77
Effects of acupuncture at HT7 on glucose metabolism in a rat model of Alzheimer's disease: an 18F-FDG-PET study. Acupunct Med (2015) 0.77
Plasma F2-isoprostane level and cognitive function over eight years in non-demented older adults: Findings from the Health ABC Study. Prostaglandins Leukot Essent Fatty Acids (2010) 0.76
Multiplex biomarkers in blood. Alzheimers Res Ther (2013) 0.75
Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. Curr Neurol Neurosci Rep (2011) 0.75
Characterization of oxidized guanosine 5'-triphosphate as a viable inhibitor of soluble guanylyl cyclase. Free Radic Biol Med (2009) 0.75
Association of the C47T Polymorphism in SOD2 with Amnestic Mild Cognitive Impairment and Alzheimer's Disease in Carriers of the APOEε4 Allele. Dis Markers (2015) 0.75
The Role of Hypoxia-Inducible Factor 1 in Mild Cognitive Impairment. Cell Mol Neurobiol (2016) 0.75
The diabetic brain and cognition. J Neural Transm (Vienna) (2017) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med (2005) 3.13
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell (1992) 2.80
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
The human mid-size neurofilament subunit: a repeated protein sequence and the relationship of its gene to the intermediate filament gene family. EMBO J (1987) 2.72
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Platelet activation in unstable coronary disease. N Engl J Med (1986) 2.60
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell (2001) 2.59
Effects of vitamin E on lipid peroxidation in healthy persons. JAMA (2001) 2.58
Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J Neurosci (1992) 2.50
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci (1998) 2.43
CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology (2008) 2.43
Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem (2000) 2.42
The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med (1989) 2.36
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage (2008) 2.36
Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest (1992) 2.30
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A (1999) 2.30
No evidence for lipid peroxidation in severe preeclampsia. Am J Obstet Gynecol (2001) 2.28
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A (1999) 2.26
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest (2001) 2.19
Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest (1981) 2.18
Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology (2005) 2.18
Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 2.16
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med (1997) 2.15
Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci (1987) 2.15
Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem (1999) 2.13
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron (1994) 2.13
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A (1998) 2.13
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem (1997) 2.12
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10
Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology (2005) 2.10
Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology (2007) 2.09